Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) CEO Greg Madison speaks to Thomas Warner from Proactive after the commercial-stage specialty pharmaceutical.
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said its Accrufer iron deficiency treatment saw 173% growth in prescriptions in the second quarter, or a 50%.
Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Sees strong prescription.
By Joe Hoppe Shield Therapeutics shares rose Thursday after the company said U.S. prescriptions for its Accrufer product for iron deficiency rose 50% on.